Clough Capital Partners’s Precigen PGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
Sell
-129,569
Closed -$3.12M 137
2017
Q2
$3.12M Sell
129,569
-7,205
-5% -$158K 0.22% 79
2017
Q1
$2.71M Sell
136,774
-22,177
-14% -$495K 0.17% 86
2016
Q4
$3.83M Buy
158,951
+104,030
+189% +$2.9M 0.25% 90
2016
Q3
$1.52M Sell
54,921
-3,078
-5% -$81.4K 0.08% 125
2016
Q2
$1.42M Sell
57,999
-95,574
-62% -$2.71M 0.08% 135
2016
Q1
$5.16M Sell
153,573
-290,881
-65% -$9.16M 0.24% 105
2015
Q4
$13.3M Buy
444,454
+218,672
+97% +$7.37M 0.62% 57
2015
Q3
$7.12M Sell
225,782
-295,803
-57% -$14.4M 0.31% 79
2015
Q2
$25.2M Sell
521,585
-111,586
-18% -$4.7M 0.96% 32
2015
Q1
$27.5M Sell
633,171
-481,031
-43% -$17.3M 0.91% 37
2014
Q4
$29.3M Sell
1,114,202
-657
-0.1% -$14.4K 1.05% 27
2014
Q3
$19.8M Sell
1,114,859
-22,078
-2% -$451K 0.74% 52
2014
Q2
$27.3M Buy
1,136,937
+474,930
+72% +$9.63M 0.86% 36
2014
Q1
$16.6M Buy
662,007
+489,500
+284% +$13.6M 0.52% 76
2013
Q4
$3.92M Buy
+172,507
New +$3.49M 0.13% 144

Other funds holding PGEN

Clough Capital Partners's PGEN Position: Q3 2017 in Review

Clough Capital Partners sold out of Precigen (PGEN) in Q3 2017, closing a stake of 129,569 shares — an estimated $3.12M sold.

Clough Capital Partners first reported a position in PGEN in Q4 2013 and held it in 15 quarters. The position peaked at $29.3M in Q4 2014. 155 funds tracked by Wall St. Rank hold PGEN as of Q3 2017.

  • Clough Capital Partners reported no remaining Precigen position as of Q3 2017 after selling out during the quarter.
  • Clough Capital Partners sold 129,569 Precigen shares in Q3 2017, an estimated $3.12M.
  • Clough Capital Partners first reported a position in Precigen in Q4 2013 and held it in 15 quarters.
  • Clough Capital Partners's Precigen position peaked at $29.3M in Q4 2014.
  • 155 funds tracked by Wall St. Rank held Precigen as of Q3 2017.

Based on Clough Capital Partners's 13F filing for Q3 2017, filed 14 Nov 2017.